07:00 , Mar 11, 2013 |  BC Week In Review  |  Company News

AmorePacific, Brickell Biotech deal

AmorePacific Corp. (KSE:090430), Seoul, South Korea   Brickell Biotech Inc. , Miami, Fla.   Business: Dermatology   AmorePacific's AmorePacific Ventures corporate venture fund gained an option of first negotiation to license exclusive rights to two...
08:00 , Mar 4, 2013 |  BC Week In Review  |  Financial News

Brickell Biotech completes venture financing

Brickell Biotech Inc. , Miami, Fla.   Business: Dermatology, Ophthalmic   Date completed: 2/26/13   Type: Venture financing   Raised: Not disclosed   Investors: Amorepacific Ventures; Palisade Capital; existing investors   Note: The company raised...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Financial News

Lithera completes venture financing

Lithera Inc. , San Diego, Calif.   Business: Ophthalmic, Endocrine/Metabolic   Date completed: 12/19/12   Type: Venture financing   Raised: $20.6 million   Investors: Rusnano; Domain Associates; Alta Partners; Amorepacific Ventures; Numoda Capital Innovations  ...
01:32 , Dec 20, 2012 |  BC Extra  |  Financial News

Lithera raises $20.6 million

Lithera Inc. (San Diego, Calif.) raised $20.6 million in an undisclosed venture round led by Rusnano. Existing investors Domain Associates and Alta Partners also participated, along with new investors Amorepacific Ventures and Numoda Capital Innovations....
08:00 , Dec 22, 2008 |  BioCentury  |  Product Development

Taking homework seriously

Despite having top-line Phase IIa data in hand showing efficacy for its NSAID in osteoarthritis, CrystalGenomics Inc. 's CG Pharmaceuticals Inc. unit is not rushing to get to Phase III. Instead, it is fleshing out...
07:00 , Jun 6, 2005 |  BioCentury  |  Product Development

VR1 pipeline

VR1 pipeline Company Product Description Indication Status (Milestone) NeurogesX NGX-4010 VR1 agonist topical patch Postherpetic neuralgia (PHN); pain related to HIV-associated neuropathy (HIV-AN) Ph III (submit for EU approval 2H06; submit NDA mid-2007) Winston Labs...
08:00 , Mar 1, 2004 |  BioCentury  |  Strategy

East looks West

While Asia's homegrown biotech has been largely invisible in the West, the pattern may begin to change as the newer players recognize the need to gain access to large markets in the U.S. and Europe....
08:00 , Feb 23, 2004 |  BC Week In Review  |  Company News

Schwarz Pharma, AmorePacific Corp. deal

Schwarz received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid receptor 1 ( VR1 ) antagonist and back-up compounds to treat pain and urinary incontinence. Schwarz's rights exclude dermatology indications and the...
08:00 , Feb 20, 2004 |  BC Extra  |  Company News

Schwarz, AmorePacific pain deal

Schwarz Pharma (Monheim, Germany) received exclusive global rights to develop, market and manufacture AmorePacific's PAC20030 vanilloid receptor 1 ( VR1 ) antagonist and back-up compounds to treat pain and urinary incontinence. Schwarz's rights exclude dermatology...